To determine whether PD-1 immune-checkpoint blockade combined with the immunomodulator SMI is more effective than PD-1 inhibitor monotherapy in treating NSCLC, the LLC subcutaneous C57BL/6 mouse model was first adopted to detect the efficacy and safety of this combined therapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.